These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 12660383

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
    Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG.
    N Engl J Med; 2003 Mar 27; 348(13):1201-14. PubMed ID: 12660384
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A, Duggal L, Aggarwal S, Jain N.
    J Assoc Physicians India; 2006 Nov 27; 54():883-6. PubMed ID: 17249259
    [Abstract] [Full Text] [Related]

  • 5. From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
    Friedrich MJ.
    J Natl Cancer Inst; 2003 Aug 06; 95(15):1102-3. PubMed ID: 12902432
    [No Abstract] [Full Text] [Related]

  • 6. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
    Musto P, Perla G, Minervini MM, Carella AM, Coco FL, Catalano G.
    Leuk Res; 2004 Jul 06; 28(7):773-4. PubMed ID: 15158099
    [No Abstract] [Full Text] [Related]

  • 7. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP, Landry J, Roche-Lestienne C, Godon A, Schmidt-Tanguy A, Gardembas M, Le Clech C, Verret JL, Zandecki M, Blanchet O.
    Ann Biol Clin (Paris); 2005 Jul 06; 63(3):317-22. PubMed ID: 15951264
    [Abstract] [Full Text] [Related]

  • 8. Imatinib and hyperlipidemia.
    Gottardi M, Manzato E, Gherlinzoni F.
    N Engl J Med; 2005 Dec 22; 353(25):2722-3. PubMed ID: 16371644
    [No Abstract] [Full Text] [Related]

  • 9. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome.
    Seshadri T, Seymour JF, McArthur GA.
    N Engl J Med; 2004 Nov 11; 351(20):2134-5. PubMed ID: 15537917
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias.
    Bain BJ.
    Br J Haematol; 2003 Jul 11; 122(2):173-9. PubMed ID: 12846884
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
    Musto P, Falcone A, Sanpaolo G, Bodenizza C, Perla G, Minervini MM, Cascavilla N, Dell'Olio M, La Sala A, Mantuano S, Melillo L, Nobile M, Scalzulli PR, Bisceglia M, Carella AM.
    Leuk Lymphoma; 2004 Jun 11; 45(6):1219-22. PubMed ID: 15360005
    [Abstract] [Full Text] [Related]

  • 14. Hypereosinophilic syndrome: diagnosis and treatment.
    Peros-Golubicić T, Smojver-Jezek S.
    Curr Opin Pulm Med; 2007 Sep 11; 13(5):422-7. PubMed ID: 17940488
    [Abstract] [Full Text] [Related]

  • 15. Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy.
    Krauth MT, Binder T, Ohler L, Jäger U, Valent P.
    Leuk Res; 2008 Nov 11; 32(11):1779-83. PubMed ID: 18417214
    [No Abstract] [Full Text] [Related]

  • 16. [The tyrosine kinase antagonist imatinib mesylate].
    Heinzl S.
    Med Monatsschr Pharm; 2002 Jan 11; 25(1):4-7. PubMed ID: 11826665
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of hypereosinophilic syndrome with imatinib mesilate.
    Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH.
    Lancet; 2002 May 04; 359(9317):1577-8. PubMed ID: 12047970
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL, Larsen H.
    Ugeskr Laeger; 2008 Jan 21; 170(4):254. PubMed ID: 18282461
    [Abstract] [Full Text] [Related]

  • 20. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L.
    J Am Acad Dermatol; 2007 May 21; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.